Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, CFO | April 20, 2022 | April 22, 2022 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Horizon Therapeutics Public Ltd Co
Report date April 20, 2022 · Filed April 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,049 |
Ending reported balance
After 2022-04-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-04-20 · Exercise / conversion · Acquired 50,000 · Balance 51,049 Row 2 · 2022-04-20 · Sale · Disposed 28,458 · Balance 22,591 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-04-20 · Sale · Disposed 21,542 · Balance 1,049 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2025-03-22 | Direct | 36,424 |
Reported balance
After 2022-04-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-04-20 · Exercise / conversion · Disposed 50,000 · Balance 36,424 F5: The option is fully vested and exercisable. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy LLC | 66,673 |
Reported balance
Holding disclosure · report date 2022-04-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 66,673 F4: The Reporting Person and his spouse share voting power over the securities held by the LLC. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 72,789 |
Reported balance
Holding disclosure · report date 2022-04-20 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 72,789 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.79 to $114.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.82 to $115.48 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The Reporting Person and his spouse share voting power over the securities held by the LLC.
F5: The option is fully vested and exercisable.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Sagimet Biosciences Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.48 · Expires 2036-06-11 | Direct | 39,567 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 39,567 · Balance 39,567 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2019 Filed Jan 9, 2019 01:36 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 65,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002933 · doc4.xml · derivative · entry 4 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,392 Underlying: Ordinary Shares · 65,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2019 Filed Jan 9, 2019 01:36 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 29,419 | $20.39 | $599,853.41 |
DisclosureSEC source: 0001209191-19-002933 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,048 Read SEC document |
| January 05, 2019 Filed Jan 9, 2019 01:36 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 65,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-002933 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:36 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 53,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002933 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 Underlying: Ordinary Shares · 53,948 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| June 23, 2018 Filed Jun 25, 2018 20:51 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039414 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest in four annual installments of 20,000 shares, on each anniversary of the vesting commencement date (June 23, 2014). F3 · derivative.expiration_date: The restricted stock units vest in four annual installments of 20,000 shares, on each anniversary of the vesting commencement date (June 23, 2014). Read SEC document |
| June 23, 2018 Filed Jun 25, 2018 20:51 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 8,860 | $17.67 | $156,556.20 |
DisclosureSEC source: 0001209191-18-039414 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,772 Read SEC document |
| June 23, 2018 Filed Jun 25, 2018 20:51 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-039414 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 2,370 ordinary shares of the Issuer acquired by the reporting person on June 1, 2018 pursuant to an employee stock purchase program. Read SEC document |
| May 03, 2018 Filed May 8, 2018 00:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 197,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028483 · doc4.xml · derivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,087 Underlying: Ordinary Shares · 197,087 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · date: The RSU's were approved by the Issuer's Compensation Committee on January 5, 2018, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the "Plan") under which the RSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 3, 2018. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021785 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Ordinary Shares · 31,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 13,733 | $13.86 | $190,339.38 |
DisclosureSEC source: 0001209191-18-021785 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,262 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:30 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-021785 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 21:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041857 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest in four annual installments of 20,000 shares, on each anniversary of the vesting commencement date (June 23, 2014). F3 · derivative.expiration_date: The restricted stock units vest in four annual installments of 20,000 shares, on each anniversary of the vesting commencement date (June 23, 2014). Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 21:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 9,140 | $11.73 | $107,212.20 |
DisclosureSEC source: 0001209191-17-041857 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,995 Read SEC document |
| June 23, 2017 Filed Jun 26, 2017 21:03 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-041857 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 1,428 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 22:29 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022836 · doc4.xml · derivative · entry 3 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Ordinary Shares · 31,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 22:29 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 14,167 | $14.56 | $206,271.52 |
DisclosureSEC source: 0001209191-17-022836 · doc4.xml · nonDerivative · entry 2 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,707 Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 22:29 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-022836 · doc4.xml · nonDerivative · entry 1 Hoelscher Paul W. · CIK 0001611468 · EVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: The number of Issuer shares previously reported as beneficially owned by the reporting person was incorrectly over reported on a prior Form 4 by 655 shares of the Issuer's common stock, and has been corrected with this filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.